The Food and Drug Administration announced Friday that Eli Lilly’s diabetes medication Mounjaro has received approval to help reduce the likelihood of heart attack or stroke in adults with type 2 diabetes who are at elevated risk for cardiovascular events. The decision follows a large, head‑to‑head clinical trial that demonstrated Mounjaro’s superiority over Lilly’s earlier GLP‑1 drug, Trulicity, in preventing major adverse heart events.
Trial results drive the new indication
In the pivotal study, participants receiving Mounjaro experienced an 8% greater reduction in the composite endpoint of heart attack, stroke, or cardiovascular death compared with those taking Trulicity. Researchers highlighted that the drug’s ability to target the GLP‑1 protein not only improves blood‑sugar control but also appears to confer cardiovascular protection.
Implications for patients and physicians
For the millions of Americans living with type 2 diabetes, cardiovascular disease remains the leading cause of death. By expanding Mounjaro’s label to include heart‑health benefits, physicians now have an additional tool to address both glycemic control and the serious heart risks that accompany the disease. The FDA’s approval aligns with a broader trend of GLP‑1 therapies being evaluated for multiple health outcomes beyond weight loss.
Market impact and competition
Sales of Mounjaro surged 91% in the most recent quarter, reaching $9.94 billion as demand grew across global markets. The drug’s dual role in diabetes management and weight reduction—sold under the brand name Zepbound for obesity—has positioned it as a key growth driver for Lilly.
Industry rivals, most notably Danish pharmaceutical giant Novo Nordisk, are also expanding the reach of their own GLP‑1 products, testing them in a range of conditions from cardiovascular disease to liver disorders. The competitive landscape suggests that patients may soon see a broader array of treatment options that address both metabolic and heart‑health concerns.
What’s next?
Lilly plans to continue gathering real‑world evidence on Mounjaro’s cardiovascular benefits while exploring additional indications. Health‑care providers are encouraged to consider the new data when evaluating treatment plans for patients with type 2 diabetes who have a high risk of heart disease.
As the FDA’s decision underscores, advances in diabetes therapeutics are increasingly intertwined with cardiovascular health, offering hope for better outcomes for a condition that affects more than 34 million Americans.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
